Axsome Therapeutics Inc. logo

Axsome Therapeutics Inc. (AXSM)

Market Closed
3 Jul, 20:00
NASDAQ (NMS) NASDAQ (NMS)
$
105. 44
+1.53
+1.47%
$
5.09B Market Cap
- P/E Ratio
0% Div Yield
245,800 Volume
-4.27 Eps
$ 103.91
Previous Close
Day Range
103.96 106.63
Year Range
72.21 139.13
Want to track AXSM and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Earnings results expected in 37 days

Summary

AXSM closed Thursday higher at $105.44, an increase of 1.47% from Wednesday's close, completing a monthly increase of 0.08% or $0.08. Over the past 12 months, AXSM stock gained 23.68%.
AXSM is not paying dividends to its shareholders.
The last earnings report, released on May 05, 2025, missed the consensus estimates by -0.01%. On average, the company has fell short of earnings expectations by -0.16%, based on the last three reports. The next scheduled earnings report is due on Aug 11, 2025.
The stock of the company had never split.
The company's stock is traded on 7 different exchanges and in various currencies, with the primary listing on NASDAQ (NMS) (USD).

AXSM Chart

Chart

Chart with 60 data points.
The chart has 1 X axis displaying categories.
The chart has 2 Y axes displaying values, and values.
End of interactive chart.
Axsome Therapeutics Champions Brain Health During Alzheimer's & Brain Awareness Month

Axsome Therapeutics Champions Brain Health During Alzheimer's & Brain Awareness Month

NEW YORK, June 20, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today is joining with the Alzheimer's disease advocacy community to raise awareness of the growing impact of Alzheimer's disease in the United States and the importance of brain health during this year's Alzheimer's & Brain Awareness Month.

Globenewswire | 2 weeks ago
Why Is Axsome (AXSM) Down 1.8% Since Last Earnings Report?

Why Is Axsome (AXSM) Down 1.8% Since Last Earnings Report?

Axsome (AXSM) reported earnings 30 days ago. What's next for the stock?

Zacks | 1 month ago
Axsome Therapeutics to Participate in Upcoming Investor Conferences

Axsome Therapeutics to Participate in Upcoming Investor Conferences

NEW YORK, May 29, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced that it will participate in three upcoming investor conferences in June:

Globenewswire | 1 month ago

Axsome Therapeutics Inc. Dividends

AXSM is not paying dividends to its shareholders.

Axsome Therapeutics Inc. Earnings

11 Aug 2025 (In 1 month) Date
-
Cons. EPS
-
EPS
5 May 2025 Date
-
Cons. EPS
-
EPS
18 Feb 2025 Date
-
Cons. EPS
-
EPS
12 Nov 2024 Date
-
Cons. EPS
-
EPS
4 Nov 2024 Date
-
Cons. EPS
-
EPS
AXSM is not paying dividends to its shareholders.
11 Aug 2025 (In 1 month) Date
-
Cons. EPS
-
EPS
5 May 2025 Date
-
Cons. EPS
-
EPS
18 Feb 2025 Date
-
Cons. EPS
-
EPS
12 Nov 2024 Date
-
Cons. EPS
-
EPS
4 Nov 2024 Date
-
Cons. EPS
-
EPS

Axsome Therapeutics Inc. (AXSM) FAQ

What is the stock price today?

The current price is $105.44.

On which exchange is it traded?

Axsome Therapeutics Inc. is listed on NASDAQ (NMS).

What is its stock symbol?

The ticker symbol is AXSM.

Does it pay dividends? What is the current yield?

Yes, It pays dividends and the current yield is 0%.

What is its market cap?

As of today, the market cap is 5.09B.

When is the next earnings date?

The next earnings report will release on Aug 11, 2025.

Has Axsome Therapeutics Inc. ever had a stock split?

No, there has never been a stock split.

Axsome Therapeutics Inc. Profile

Biotechnology Industry
Healthcare Sector
Herriot Tabuteau CEO
NASDAQ (NMS) Exchange
05464T104 Cusip
US Country
712 Employees
- Last Dividend
- Last Split
19 Nov 2015 IPO Date

Overview

Axsome Therapeutics, Inc. is a forward-thinking biopharmaceutical entity dedicated to the innovation of novel treatments geared towards addressing the complexities of central nervous system (CNS) disorders. Rooted in the quest to improve patient care within the United States, Axsome stands out for its dynamic approach towards tackling conditions such as major depressive disorder, narcolepsy, obstructive sleep apnea, Alzheimer's disease agitation, and more. The foundation of the company's operations, established in 2012 and headquartered in New York, New York, underscores a commitment to pushing the boundaries of medical science, particularly in the CNS domain. Through its research collaboration with Duke University focused on smoking cessation, Axsome exemplifies its dedication to pioneering efforts in enhancing therapeutic outcomes.

Products and Services

  • Auvelity (dextromethorphan-bupropion): An innovative N-methyl-D-aspartate receptor antagonist showcasing multimodal activity, specifically indicated for the treatment of major depressive disorder, highlighting Axsome's focus on addressing mental health challenges with novel approaches.
  • Sunosi (solriamfetol): A targeted medication addressing excessive daytime sleepiness in patients battling narcolepsy or obstructive sleep apnea, underlining the company's dedication to improving quality of life for individuals with sleep disorders.

Under Development:

  • AXS-05: Currently in Phase III clinical trial for Alzheimer's disease agitation, showcasing Axsome's deep dive into neurodegenerative disease management. Additionally, it demonstrates versatility with its completion of Phase II clinical trial for smoking cessation.
  • AXS-07: An investigational medicine that has successfully completed Phase III trials, crafted for the acute treatment of migraine, providing a glimpse into Axsome's commitment to tackling severe headache disorders.
  • AXS-12: In Phase III trial to treat narcolepsy, positioning Axsome at the forefront of addressing sleep disorders with cutting-edge solutions.
  • AXS-14: Having completed Phase III trial for the treatment of fibromyalgia, this selective and potent norepinephrine reuptake inhibitor represents Axsome's venture into pain management and other potential conditions.
  • Solriamfetol: Beyond its approved use, it is under investigation in a Phase 2 trial for addressing attention-deficit/hyperactivity disorder. Additionally, its exploration extends to major depressive, binge eating, and shift work disorders, showing Axsome's holistic approach to CNS conditions.

Contact Information

Address: 22 Cortlandt Street
Phone: 212 332 3241